Eli Lilly and Company ($LLY) Stock Forecast: Up 5.0% Today

What is Eli Lilly and Company?

Eli Lilly and Company (NYSE: LLY) is a pharmaceutical giant with a reputation for innovative medications. The stock experienced a strong bullish movement today.

Why is Eli Lilly and Company going up?

LLY stock is up 5.0% on Nov 5, 2025 14:55

• Eli Lilly's $149 obesity drug deal with the White House has excited investors, fueling optimism for increased revenue and market share.
• The company's announcement of a substantial European manufacturing expansion for oral medicine has likely bolstered investor confidence in its growth potential.
• Surpassing expectations for third-quarter earnings and raising the annual forecast have contributed to the positive outlook on Eli Lilly, attracting more investors.
• The impressive performance of key drugs like Mounjaro and Zepbound, resulting in a notable revenue increase, has further reinforced Eli Lilly's growth prospects and driven up the stock price.

LLY Price Chart

LLY Technical Analysis

LLY News

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House - Eli Lilly ( NYSE:LLY )

Eli Lilly and Company ( NYSE:LLY ) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement ...

https://www.benzinga.com/trading-ideas/movers/25/11/48634128/eli-lilly-novo-nordisk-stocks-rise-on-reported-149-obesity-drug-deal-with-white-house

What's Up With The Rise In Eli Lilly Stock Today? - Eli Lilly ( NYSE:LLY )

Eli Lilly and Company ( NYSE:LLY ) shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion for oral medicine. LLY is in positive territory. See what is driving the move here.

https://www.benzinga.com/trading-ideas/movers/25/11/48600933/whats-up-with-the-rise-in-eli-lilly-stock-today

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say - Eli Lilly ( NYSE:LLY )

Eli Lilly and Co. ( NYSE:LLY ) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher. The U.S. weight loss drug giant reported quarterly revenue of $17.60 billion, up 54% year over year, beating the consensus of $16.02 ...

https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48571020/eli-lilly-seen-in-pole-position-for-growth-analysts-say

Company News for Oct 31, 2025

Companies in The News Are: ...

https://www.zacks.com/stock/news/2782675/company-news-for-oct-31-2025

Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.

https://www.zacks.com/stock/news/2781842/lilly-beats-on-q3-earnings-ups-view-mounjaro-zepbound-drive-sales

Trending Today

Uniswap ($UNI) Crypto Forecast: Up 43.2% Today

XRP ($XRP) Crypto Forecast: Up 8.5% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Down 5.1% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.0% Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Up 5.1% Today

American Electric Power Company Inc. ($AEP) Stock Forecast: Down 0.4% Today

Duke Energy Corporation (Holding Company) ($DUK) Stock Forecast: Down 0.2% Today

Novavax Inc. ($NVAX) Stock Forecast: Down 5.1% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 9.2% Today

QuantumScape Corp. ($QS) Stock Forecast: Down 8.3% Today

Eli Lilly and Company Price History

15.07.2025 - LLY Stock was up 5.1%

• Eli Lilly stock climbed significantly today, driven by several factors:
• The UK monthly price increase for Mounjaro's highest dose and the pricing adjustment in India's Mounjaro Kwikpen likely contributed to the positive movement.
• Insider moves within the company, such as bold buys and record sales, may have boosted investor confidence.
• Speculation around undervalued healthcare stocks, including Eli Lilly, could have attracted buyers looking for potential growth opportunities.

26.07.2025 - LLY Stock was up 5.0%

• Eli Lilly stock surged after positive results from its oral GLP-1 pill trial, which demonstrated impressive weight loss benefits and blood sugar level reductions.
• The success of the weight-loss pill trial has fueled investor optimism and confidence in Eli Lilly's future growth prospects.
• Despite a setback with its orforglipron pill, the company's robust late-stage pipeline continues to support expectations for sustained growth and innovation in the pharmaceutical sector.
• The investigation by the Portnoy Law Firm into Eli Lilly's activities does not seem to have impacted the stock's bullish momentum, indicating that investors are primarily focused on the positive trial results and growth potential.

30.09.2025 - LLY Stock was up 2.0%

• Eli Lilly (LLY) surpassed Q3 earnings and revenue expectations, demonstrating robust financial performance.
• Collaboration with NVIDIA on a high-performance supercomputer underscores Lilly's dedication to technological advancements in pharmaceutical research.
• Aggressive acquisitions in the biotech and gene therapy sectors signal a strategic effort to diversify its pipeline and spur long-term growth.
• Positive views from Wall Street and Buy recommendations are boosting investor confidence and contributing to the upward trend of the stock.

29.06.2025 - LLY Stock was down 5.2%

• The company witnessed a bearish movement in its stock performance.
• Reduced sales growth outlook of a competitor and concerns over illegal weight-loss drug imports impacting a specific drug category may have influenced overall market sentiment towards the company.
• Despite positive news of a drug recommendation for Alzheimer's disease, it may not have fully offset the prevailing negative market sentiment.
• The bearish stance taken by investors through options trading likely contributed to the stock's decline.

29.06.2025 - LLY Stock was down 6.1%

• The decline in Eli Lilly's stock could be linked to investors taking a bearish stance in options trading, as shown by publicly available options history.
• Concerns raised by Congress about the illegal import of weight-loss drugs from China, which also mentioned Eli Lilly, may have further dampened investor sentiment.
• While Eli Lilly received positive news of early Alzheimer's drug approval recommendation in Europe, the market seemed more influenced by general pessimism and regulatory risks.
• The conclusion of the Verve tender offer involving Eli Lilly likely impacted investor sentiment and contributed to the stock's bearish movement.

29.06.2025 - LLY Stock was down 6.7%

• The bearish movement in LLY stock could be attributed to concerns raised by Congress over illegal weight-loss drug imports from China, which might impact the company's reputation and sales.
• Despite the positive news of Eli Lilly's early Alzheimer's drug recommendation for approval in Europe, the market might be reacting more to the potential safety risks associated with illegal drug imports.
• Investors might be cautious about the upcoming Q2 earnings report, especially regarding the performance of Eli Lilly's oncology drugs, as any underperformance could have contributed to the bearish trend.
• The expiration of the Verve tender offer might also be a factor in the stock's movement, signaling potential shifts in the company's strategic partnerships or future developments.

05.10.2025 - LLY Stock was up 5.0%

• Eli Lilly's $149 obesity drug deal with the White House has excited investors, fueling optimism for increased revenue and market share.
• The company's announcement of a substantial European manufacturing expansion for oral medicine has likely bolstered investor confidence in its growth potential.
• Surpassing expectations for third-quarter earnings and raising the annual forecast have contributed to the positive outlook on Eli Lilly, attracting more investors.
• The impressive performance of key drugs like Mounjaro and Zepbound, resulting in a notable revenue increase, has further reinforced Eli Lilly's growth prospects and driven up the stock price.

07.07.2025 - LLY Stock was down 13.3%

• Despite surpassing earnings and revenue estimates in Q2, Eli Lilly's stock experienced a bearish movement.
• The disappointment in the weight loss results of Orforglipron compared to financial forecasts may have contributed to the stock's decline.
• Threats of imposing high tariffs on pharmaceutical imports could have added uncertainty to the market, impacting Eli Lilly's stock negatively.
• The reversal of early weakness and the climb of 1.8% towards the end of the day could indicate some resilience in the stock, potentially driven by positive trading signals and smart money inflow.

01.09.2025 - LLY Stock was up 11.2%

• Eli Lilly's stock (LLY) has seen a bullish trend, driven by encouraging recommendations from financial analysts on Wall Street, signaling a buy outlook among investors.
• Remarkably, Pfizer's agreement with the Trump administration concerning drug pricing has had a constructive impact on the pharmaceutical industry, including companies like Eli Lilly.
• Investor confidence, potentially from institutions or high-net-worth individuals, in Eli Lilly has intensified the upward trajectory of its stock.
• Additionally, Amgen's enhancement of its U.S. manufacturing footprint amid evolving tariff regulations could have indirectly contributed to the positive market sentiment around pharmaceutical firms like Eli Lilly.

01.09.2025 - LLY Stock was up 8.4%

• Eli Lilly's stock surged due to an announcement by President Donald Trump regarding a deal with Pfizer, which included the 'TrumpRx' platform aimed at reducing drug prices. This news boosted investor confidence in the pharmaceutical sector.
• The partnership between Pfizer and Washington had a significant impact on the industry, leading to companies like Eli Lilly benefiting from the positive market sentiment.
• Furthermore, bullish bets from high-net-worth investors, as reflected in publicly available options history, added to the upward momentum in Eli Lilly's stock.
• The overall optimism surrounding Eli Lilly, along with strategic expansions and favorable analyst recommendations, played key roles in the stock's impressive performance on the day.

17.06.2025 - LLY Stock was down 3.4%

• Eli Lilly's stock (LLY) faced a bearish trend, potentially influenced by concerns regarding its valuation despite a strong performance in the last decade.
• The negative stance taken by significant investors towards LLY options could have contributed to the stock's downward pressure.
• Even though drugs like Mounjaro and Zepbound hold promise for driving robust quarterly earnings, the prevailing market sentiment towards Eli Lilly was mostly unfavorable, resulting in the bearish movement.

30.08.2025 - LLY Stock was up 5.3%

• Eli Lilly (LLY) stock surged due to positive market sentiment and investor confidence in the company's growth prospects.
• The bullish stance taken by investors, including institutions and high-net-worth individuals, further boosted the stock's performance.
• Analysts' optimistic recommendations and the company's strategic position in the pharmaceutical industry also contributed to the bullish movement.
• While competitors like Novo Nordisk, Amgen, and AstraZeneca made headlines, it was Lilly's own positive outlook that drove its stock price higher today.